FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 72 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following European Parliament Vote on the EU Wine Package MOST POPULAR Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent... November 24, 2025 Glucose Control Key in Reducing Cancer Risk for People with Type... December 7, 2021 Addressing Mental Health Needs of Adolescent and Young Adult Cancer Survivors March 11, 2021 The Mediterranean Diet October 30, 2020 Load more HOT NEWS Researchers at Purdue Create Filler That May Help Regenerate Tissue in... Inspired By Her Mom’s Breast Cancer Battle, Girl Sells ‘Cancer Bears’... Pregnant Mom Had to Fight for a Diagnosis After Finding a... Could A Form of Cell Death Enhance Cancer Immunotherapy?
